In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sanofi-Synthélabo closes takeover of Aventis

Executive Summary

After weeks of speculation, Sanofi-Synthélabo has launched--with the support of the French government--a hostile bid to acquire its larger rival Aventis SA for €48.3bn ($60bn)--19% in cash and 81% in stock. Sanofi claims the combined pharmaco--which would be ranked the third-largest worldwide in global sales--would have one of the largest R&D budgets in the industry (at €4bn) and would feature a pipeline of almost 60 late-stage candidates. Its therapeutic focus would include cardiovascular/thrombosis, CNS, oncology, diabetes, and urology.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies